IRC
TAK icon

Investors Research Corp’s Takeda Pharmaceutical TAK Stock Holding History

Investors Research Corp’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-725
Closed -$13.4K – 878
2026
Q1 		$13.4K Sell
725
-43,794
-98% -$769K ﹤0.01% 521
2025
Q4 		$694K Hold
44,519
– – 0.13% 154
2025
Q3 		$652K Hold
44,519
– – 0.12% 171
2025
Q2 		$688K Sell
44,519
-400
-0.9% -$5.91K 0.13% 162
2025
Q1 		$668K Buy
44,919
+1,725
+4% +$24.2K 0.14% 155
2024
Q4 		$572K Sell
43,194
-2,600
-6% -$35.7K 0.13% 177
2024
Q3 		$651K Hold
45,794
– – 0.14% 173
2024
Q2 		$593K Hold
45,794
– – 0.14% 181
2024
Q1 		$636K Sell
45,794
-2,012
-4% -$29.3K 0.15% 177
2023
Q4 		$682K Sell
47,806
-313
-0.7% -$4.44K 0.16% 160
2023
Q3 		$744K Hold
48,119
– – 0.19% 140
2023
Q2 		$756K Sell
48,119
-2,000
-4% -$32.8K 0.19% 144
2023
Q1 		$826K Hold
50,119
– – 0.21% 125
2022
Q4 		$782K Sell
50,119
-200
-0.4% -$2.79K 0.21% 128
2022
Q3 		$653K Hold
50,319
– – 0.2% 143
2022
Q2 		$706K Buy
50,319
+3,450
+7% +$49.2K 0.21% 140
2022
Q1 		$671K Buy
46,869
+12,900
+38% +$189K 0.19% 146
2021
Q4 		$463K Buy
33,969
+10,003
+42% +$140K 0.14% 196
2021
Q3 		$393K Hold
23,966
– – 0.13% 205
2021
Q2 		$403K Hold
23,966
– – 0.14% 203
2021
Q1 		$438K Sell
23,966
-1,075
-4% -$19.3K 0.17% 191
2020
Q4 		$456K Buy
25,041
+450
+2% +$7.89K 0.18% 192
2020
Q3 		$439K Buy
24,591
+23,550
+2,262% +$429K 0.21% 153
2020
Q2 		$19K Hold
1,041
– – 0.01% 688
2020
Q1 		$16K Hold
1,041
– – 0.01% 676
2019
Q4 		$21K Hold
1,041
– – 0.01% 704
2019
Q3 		$18K Hold
1,041
– – 0.01% 732
2019
Q2 		$18K Hold
1,041
– – 0.01% 724
2019
Q1 		$21K Buy
+1,041
New +$20.9K 0.01% 671

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Investors Research Corp's TAK Position: Q2 2026 in Review

Investors Research Corp sold out of Takeda Pharmaceutical (TAK) in Q2 2026, closing a stake of 725 shares — an estimated $13.4K sold.

Investors Research Corp first reported a position in TAK in Q1 2019 and held it in 29 quarters. The position peaked at $826K in Q1 2023. 375 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Investors Research Corp reported no remaining Takeda Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Investors Research Corp sold 725 Takeda Pharmaceutical shares in Q2 2026, an estimated $13.4K.
  • Investors Research Corp first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 29 quarters.
  • Investors Research Corp's Takeda Pharmaceutical position peaked at $826K in Q1 2023.
  • 375 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Investors Research Corp's 13F filing for Q2 2026, filed 10 Jul 2026.